Parthenogenetic Stem Cell Lines for Immune Compatibility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current human embryonic stem cell therapies face challenges with immune rejection due to HLA matching issues, limiting the effectiveness of transplant-based stem cell therapies, and existing methods for generating HLA-matched stem cells are complex and ethically contentious.
Innovation Solution
The development of HLA homozygous parthenogenetic human stem cell lines derived from both HLA homozygous and heterozygous donors, which are genetically identical to the oocyte donor, minimizing the use of animal-derived components and ensuring MHC compatibility, thereby reducing the risk of immune rejection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HLA-matched stem cells are used to reduce immune rejection, then transplant survival is improved, but the complexity of finding matched donors increases
Solution Approach 1:
The patent creates stem cell lines that are genetic copies of the patient through parthenogenetic activation, where the oocyte is activated to develop into a blastocyst containing cells with the patient's HLA alleles. This copying approach eliminates the need to search for unrelated HLA-matched donors, as the patient's own gametes serve as the source for generating histocompatible stem cells.
Solution Approach 2:
The patient's own oocytes are used to generate stem cell lines that are self-compatible, meaning the stem cells inherit the patient's HLA genotype and are therefore histocompatible with the patient. This self-service approach eliminates the need for external donor matching and reduces the complexity of finding suitable donors.
2Device complexity
If parthenogenetic activation is used to generate stem cells, then HLA matching is simplified, but ethical concerns arise
Solution Approach 1:
The patent extracts and utilizes only the nuclear material from the patient's oocytes to generate stem cell lines, separating the genetic material from the cytoplasmic components. This extraction approach allows for the generation of HLA-matched stem cells while minimizing ethical concerns by using minimal invasive procedures and ensuring the stem cells are used solely for therapeutic purposes.
Solution Approach 2:
The patent performs preliminary genetic screening and counseling to ensure that parthenogenetic activation is appropriate for the patient and that the generated stem cells will be used for approved therapeutic indications. This preliminary action helps address ethical concerns by ensuring informed consent and appropriate use before the procedure is performed.
3Reliability
If autologous stem cell transplantation is performed, then immune rejection is minimized, but the complexity of generating patient-specific cells increases
Solution Approach 1:
The patent creates genetic copies of the patient's stem cells through parthenogenetic activation, producing autologous stem cell lines that are identical to the patient's HLA genotype. This copying approach ensures immune compatibility while using a relatively straightforward activation process compared to more complex methods like somatic cell nuclear transfer.
Solution Approach 2:
The patent utilizes changes in the developmental state of the oocyte, transitioning it from a mature gamete through parthenogenetic activation to a blastocyst stage suitable for stem cell derivation. This parameter change approach simplifies the overall process by leveraging natural developmental transitions rather than requiring complex manipulation techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The generated stem cell lines demonstrate high levels of alkaline phosphatase and telomerase activity, maintain pluripotency, and can differentiate into various cell types, offering a promising solution for clinical applications by minimizing immune rejection and ethical concerns.
Implementation Method 1
Parthenogenetic activation of mammalian oocytes may be used as an alterative to fertilization by sperm/NT to prepare oocytes for embryonic stem cell generation. Parthenogenetic activation is the production of embryonic cells, with or without eventual development into an adult, from a female gamete in the absence of any contribution from a male gamete.
Implementation Method 2
ES cells become differentiated into neurons in the presence of nerve growth factor and retinoic acid.
Data Source
Figure 1A~1
Figure 1
Figure 2
AI summary
Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application.